The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Breast cancer is the most frequently diagnosed malignancy worldwide and the leading
cause of cancer-related death among women. Brain metastases are a primary contributor to …

Objective: This study aimed to investigate the prevalence of tumor programmed death-ligand
1 (PD-L1) expression in Chinese patients with advanced Non-Small Cell Lung Cancer …

The brain is one of the most common metastatic sites in non-small cell lung cancer
(NSCLC), which is associated with an extremely poor prognosis. Despite the availability of …

Brain metastases (BMs) in non-small-cell lung cancer (NSCLC) patients are associated with
significant morbidity and poor prognosis. Immune checkpoint inhibitors (ICIs) have resulted …

Opinion statement Systemic therapy for brain metastases (BM) is quickly moving from
conventional cytotoxic chemotherapy toward targeted therapies, that allow a disruption of …

Importance Patients with brain metastases from non–small cell lung cancer (NSCLC) have
regularly been excluded from prospective clinical trials that include therapy with immune …

Brain metastases stemming from lung cancer represent a common and challenging
complication that significantly impacts patients' overall health. The migration of these …

About 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases
(BMs) throughout the disease, and the occurrence of BMs is considered to have a fairly high …

Simple Summary Chordoma patients may be amenable to immunotherapy; however, the
immune microenvironment of chordomas needs further investigation. We performed the …